Programa de trasplantes de hígado

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. A Study to Evaluate the Safety and Effectiveness of BMS-986036 (pegbelfermin) in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Fibrosis

   Jacksonville, Fla.

   The purpose of this study is to confirm and extend the results observed in the Phase 1 and 2a studies with BMS-986036. Specifically, this study aims to demonstrate in participants with NASH and compensated cirrhosis, the effectiveness of BMS-986036 using histological and noninvasive endpoints, and the safety of BMS-986036 as assessed by AEs, lab results and bone mineral density (BMD) monitoring.

2. Validation of Cognitive Tests in Elderly Cirrhotic Patients

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to define the prevalence and impact of cognitive impairment and their impact on HRQOL in elderly patients with cirrhosis compared to elderly patients without cirrhosis.

3. A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis - FALCON 1 Study

   Jacksonville, Fla.

   The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).

4. A Study to Develop a Breath Analysis Test

   Jacksonville, Fla.

   The purposes of this study are to establish breath sample collection and analysis techniques, to establish reference ranges for selected clinical populations, and to assess correlations between breath analysis and presence or absence of clinical or pathological evidence of disease.

    

5. A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

   Scottsdale/Phoenix, Ariz.

   This is a 5-year, longitudinal, observational study of patients with PBC designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.

6. A Study of Using Ultrasound to Evaluate Post-Transplant Acute Liver Rejection

   Rochester, Minn.

   Liver biopsy is routinely performed at day 7 after liver transplant at Mayo to evaluate acute liver rejection.The purpose of this study is to assess the feasibility of a non-invasive evaluation of acute liver rejection by using ultrasound measurements.

7. A Study to Learn More About Children Before and After Liver Transplant

   Rochester, Minn.

   The purpose of this study is to gather information that may improve the medical care of children who need or who have had liver transplants.

8. Tissue and Blood Registry for Individuals with Liver and Biliary Tumors

   Jacksonville, Fla.

   This study will collect and store samples of tissue and blood for current and future research studies on Liver and Biliary Tumors.

9. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

10. Dose Response Study of GSK2330672 for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis

    Scottsdale/Phoenix, Ariz.

    This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Participants will be treated with either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram [mg], 90 mg or 180 mg taken once daily or 90 mg twice daily). Subjects on GSK2330672 will also receive placebo tablets to maintain blinding. The total duration of a subject's participation will be up to 45 days of screening and 24 weeks of study including follow-up.